Breast cancer is a heterogeneous disease categorized according to three therapeutic biomarkers: (1) estrogen receptor (ER)-positive cancer, (2) HER2 (ERBB2)-amplified cancer, and (3) triple-negative cancer. This evidence concerns the gene ESR1 and breast carcinoma.